Ceftobiprole is superior to vancomycin, daptomycin, and linezolid for treatment of experimental endocarditis in rabbits caused by methicillin- resistant Staphylococcus aureus

Antimicrobial Agents and Chemotherapy

Volumn 54, Issue 2, 2010, Pages 610-613

  Tattevin, P ^a   Basuino, L ^a   Bauer, D ^a   Diep, B A ^a   Chambers, H F ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CEFTOBIPROLE; DAPTOMYCIN; LINEZOLID; VANCOMYCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA VALVE; ARTICLE; BACTERIAL COLONIZATION; BACTERIAL ENDOCARDITIS; BACTERIAL STRAIN; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG EFFICACY; EXPERIMENTAL ENDOCARDITIS; EXPERIMENTAL INFECTION; EXPERIMENTAL RABBIT; KIDNEY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NONHUMAN; PRIORITY JOURNAL; SPLEEN;

ACETAMIDES; ANIMALS; ANTI-BACTERIAL AGENTS; CEPHALOSPORINS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DAPTOMYCIN; DISEASE MODELS, ANIMAL; ENDOCARDITIS, BACTERIAL; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; OXAZOLIDINONES; RABBITS; RANDOM ALLOCATION; VANCOMYCIN;

EID: 75749120582     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00886-09     Document Type: Article

References (37)

1. Anonymous. 2006. Ceftobiprole medocaril: BAL5788, JNJ 30982081, JNJ30982081, RO 65-5788, RO 655788. Drugs R D 7:305-311.
2. Baddour, L. M., W. R. Wilson, A. S. Bayer, V. G. Fowler, Jr., A. F. Bolger, M. E. Levison, P. Ferrieri, M. A. Gerber, L. Y. Tani, M. H. Gewitz, D. C. Tong, J. M. Steckelberg, R. S. Baltimore, S. T. Shulman, J. C. Burns, D. A. Falace, J. W. Newburger, T. J. Pallasch, M. Takahashi, and K. A. Taubert. 2005. Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications: a statement for healthcare professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association: endorsed by the Infectious Diseases Society of America. Circulation 111:e394-e434.
3. Boucher, H. W., and G. R. Corey. 2008. Epidemiology of methicillin-resistant Staphylococcus aureus. Clin. Infect. Dis. 46(Suppl. 5):S344-S349.
4. Boucher, H. W., and G. Sakoulas. 2007. Perspectives on Daptomycin resistance, with emphasis on resistance in Staphylococcus aureus. Clin. Infect. Dis. 45:601-608.
5. Bush, K., M. Heep, M. J. Macielag, and G. J. Noel. 2007. Anti-MRSA beta-lactams in development, with a focus on ceftobiprole: the first anti-MRSA beta-lactam to demonstrate clinical efficacy. Expert Opin. Investig. Drugs 16:419-429.
6. Cha, R., R. G. Grucz, Jr., and M. J. Rybak. 2003. Daptomycin dose-effect relationship against resistant gram-positive organisms. Antimicrob. Agents Chemother. 47:1598-1603.
7. Chambers, H. F. 2006. Ceftobiprole: in-vivo profile of a bactericidal cephalosporin. Clin. Microbiol. Infect. 12(Suppl. 2):17-22.
8. Chambers, H. F. 2001. The changing epidemiology of Staphylococcus aureus? Emerg. Infect. Dis. 7:178-182.
9. Chambers, H. F. 2005. Evaluation of ceftobiprole in a rabbit model of aortic valve endocarditis due to methicillin-resistant and vancomycin-intermediate Staphylococcus aureus. Antimicrob. Agents Chemother. 49:884-888.
10. Chambers, H. F., and S. S. Hegde. 2007. Combating the growing problem of methicillin-resistant Staphylococcus aureus: do the newer antibiotics represent a better alternative to vancomycin? Expert Rev. Anti Infect. Ther. 5:333-335.
11. Chiang, F. Y., and M. Climo. 2003. Efficacy of linezolid alone or in combination with vancomycin for treatment of experimental endocarditis due to methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 47:3002-3004.
12. Cosgrove, S. E., and V. G. Fowler, Jr. 2008. Management of methicillinresistant Staphylococcus aureus bacteremia. Clin. Infect. Dis. 46(Suppl. 5): S386-S393.
13. Dailey, C. F., C. L. Dileto-Fang, L. V. Buchanan, M. P. Oramas-Shirey, D. H. Batts, C. W. Ford, and J. K. Gibson. 2001. Efficacy of linezolid in treatment of experimental endocarditis caused by methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 45:2304-2308.
14. Entenza, J. M., P. Hohl, I. Heinze-Krauss, M. P. Glauser, and P. Moreillon. 2002. BAL9141, a novel extended-spectrum cephalosporin active against methicillin-resistant Staphylococcus aureus in treatment of experimental endocarditis. Antimicrob. Agents Chemother. 46:171-177.
15. Fowler, V. G., Jr., H. W. Boucher, G. R. Corey, E. Abrutyn, A. W. Karchmer, M. E. Rupp, D. P. Levine, H. F. Chambers, F. P. Tally, G. A. Vigliani, C. H. Cabell, A. S. Link, I. DeMeyer, S. G. Filler, M. Zervos, P. Cook, J. Parsonnet, J. M. Bernstein, C. S. Price, G. N. Forrest, G. Fatkenheuer, M. Gareca, S. J. Rehm, H. R. Brodt, A. Tice, and S. E. Cosgrove. 2006. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N. Engl. J. Med. 355:653-665.
16. Fowler, V. G., Jr., J. M. Miro, B. Hoen, C. H. Cabell, E. Abrutyn, E. Rubinstein, G. R. Corey, D. Spelman, S. F. Bradley, B. Barsic, P. A. Pappas, K. J. Anstrom, D. Wray, C. Q. Fortes, I. Anguera, E. Athan, P. Jones, J. T. van der Meer, T. S. Elliott, D. P. Levine, and A. S. Bayer. 2005. Staphylococcus aureus endocarditis: a consequence of medical progress. JAMA 293: 3012-3021.
17. Hoen, B., F. Alla, C. Selton-Suty, I. Beguinot, A. Bouvet, S. Briancon, J. P. Casalta, N. Danchin, F. Delahaye, J. Etienne, V. Le Moing, C. Leport, J. L. Mainardi, R. Ruimy, and F. Vandenesch. 2002. Changing profile of infective endocarditis: results of a 1-year survey in France. JAMA 288:75-81.
18. Jacqueline, C., N. Asseray, E. Batard, V. Le Mabecque, M. F. Kergueris, L. Dube, D. Bugnon, G. Potel, and J. Caillon. 2004. In vivo efficacy of linezolid in combination with gentamicin for the treatment of experimental endocarditis due to methicillin-resistant Staphylococcus aureus. Int. J. Antimicrob. Agents 24:393-396.
19. Jacqueline, C., E. Batard, L. Perez, D. Boutoille, A. Hamel, J. Caillon, M. F. Kergueris, G. Potel, and D. Bugnon. 2002. In vivo efficacy of continuous infusion versus intermittent dosing of linezolid compared to vancomycin in a methicillin-resistant Staphylococcus aureus rabbit endocarditis model. Antimicrob. Agents Chemother. 46:3706-3711.
20. Jacqueline, C., J. Caillon, O. Grossi, V. Le Mabecque, A. F. Miegeville, D. Bugnon, E. Batard, and G. Potel. 2006. In vitro and in vivo assessment of linezolid combined with ertapenem: a highly synergistic combination against methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 50:2547-2549.
21. Jacqueline, C., J. Caillon, V. Le Mabecque, A. F. Miegeville, A. Hamel, D. Bugnon, J. Y. Ge, and G. Potel. 2007. In vivo efficacy of ceftaroline (PPI-0903), a new broad-spectrum cephalosporin, compared with linezolid and vancomycin against methicillin-resistant and vancomycin- intermediate Staphylococcus aureus in a rabbit endocarditis model. Antimicrob. Agents Chemother. 51:3397-3400.
22. Jacqueline, C., D. Navas, E. Batard, A. F. Miegeville, V. Le Mabecque, M. F. Kergueris, D. Bugnon, G. Potel, and J. Caillon. 2005. In vitro and in vivo synergistic activities of linezolid combined with subinhibitory concentrations of imipenem against methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 49:45-51.
23. Kaatz, G. W., S. M. Seo, V. N. Reddy, E. M. Bailey, and M. J. Rybak. 1990. Daptomycin compared with teicoplanin and vancomycin for therapy of experimental Staphylococcus aureus endocarditis. Antimicrob. Agents Chemother. 34:2081-2085.
24. Marco, F., C. G. de la Maria, Y. Armero, E. Amat, D. Soy, A. Moreno, A. del Rio, M. Almela, C. A. Mestres, J. M. Gatell, M. T. Jimenez de Anta, and J. M. Miro. 2008. Daptomycin is effective in treatment of experimental endocarditis due to methicillin-resistant and glycopeptide-intermediate Staphylococcus aureus. Antimicrob. Agents Chemother. 52:2538-2543.
25. Micek, S. T. 2007. Alternatives to vancomycin for the treatment of methicillinresistant Staphylococcus aureus infections. Clin. Infect. Dis. 45(Suppl. 3):S184-S190.
26. Moore, M. R., F. Perdreau-Remington, and H. F. Chambers. 2003. Vancomycin treatment failure associated with heterogeneous vancomycin- intermediate Staphylococcus aureus in a patient with endocarditis and in the rabbit model of endocarditis. Antimicrob. Agents Chemother. 47:1262-1266.
27. Noel, G. J. 2007. Clinical profile of ceftobiprole, a novel beta-lactam antibiotic. Clin. Microbiol. Infect. 13(Suppl. 2):25-29.
28. Noel, G. J., K. Bush, P. Bagchi, J. Ianus, and R. S. Strauss. 2008. A randomized, double-blind trial comparing ceftobiprole medocaril with van-comycin plus ceftazidime for the treatment of patients with complicated skin and skin-structure infections. Clin. Infect. Dis. 46:647-655.
29. Noel, G. J., R. S. Strauss, K. Amsler, M. Heep, R. Pypstra, and J. S. Solomkin. 2008. Results of a double-blind, randomized trial of ceftobiprole treatment of complicated skin and skin structure infections caused by grampositive bacteria. Antimicrob. Agents Chemother. 52:37-44.
30. Oramas-Shirey, M. P., L. V. Buchanan, C. L. Dileto-Fang, C. F. Dailey, C. W. Ford, D. H. Batts, and J. K. Gibson. 2001. Efficacy of linezolid in a staphylococcal endocarditis rabbit model. J. Antimicrob. Chemother. 47:349-352.
31. Sakoulas, G., J. Alder, C. Thauvin-Eliopoulos, R. C. Moellering, Jr., and G. M. Eliopoulos. 2006. Induction of daptomycin heterogeneous susceptibility in Staphylococcus aureus by exposure to vancomycin. Antimicrob. Agents Chemother. 50:1581-1585.
32. Sakoulas, G., and R. C. Moellering, Jr. 2008. Increasing antibiotic resistance among methicillin-resistant Staphylococcus aureus strains. Clin. Infect. Dis. 46(Suppl. 5):S360-S367.
33. Soriano, A., F. Marco, J. A. Martinez, E. Pisos, M. Almela, V. P. Dimova, D. Alamo, M. Ortega, J. Lopez, and J. Mensa. 2008. Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia. Clin. Infect. Dis. 46:193-200.
34. Steinkraus, G., R. White, and L. Friedrich. 2007. Vancomycin MIC creep in non-vancomycin-intermediate Staphylococcus aureus (VISA), vancomycinsusceptible clinical methicillin-resistant S. aureus (MRSA) blood isolates from 2001-05. J. Antimicrob. Chemother. 60:788-794.
35. Stryjewski, M. E., L. A. Szczech, D. K. Benjamin, Jr., J. K. Inrig, Z. A. Kanafani, J. J. Engemann, V. H. Chu, M. J. Joyce, L. B. Reller, G. R. Corey, and V. G. Fowler, Jr. 2007. Use of vancomycin or first-generation cephalosporins for the treatment of hemodialysis-dependent patients with methicillin-susceptible Staphylococcus aureus bacteremia. Clin. Infect. Dis. 44:190-196.
36. Tomasz, A., S. Nachman, and H. Leaf. 1991. Stable classes of phenotypic expression in methicillin-resistant clinical isolates of staphylococci. Antimicrob. Agents Chemother. 35:124-129.
37. Widmer, A. F. 2008. Ceftobiprole: a new option for treatment of skin and soft-tissue infections due to methicillin-resistant Staphylococcus aureus. Clin. Infect. Dis. 46:656-658.